TKNO Stock Overview
Produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Alpha Teknova, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.56 |
| 52 Week High | US$7.92 |
| 52 Week Low | US$1.16 |
| Beta | 0.36 |
| 11 Month Change | 5.98% |
| 3 Month Change | 32.53% |
| 1 Year Change | 216.91% |
| 33 Year Change | -73.46% |
| 5 Year Change | n/a |
| Change since IPO | -73.76% |
Recent News & Updates
Recent updates
Revenues Tell The Story For Alpha Teknova, Inc. (NASDAQ:TKNO) As Its Stock Soars 42%
Oct 15
Alpha Teknova, Inc. (NASDAQ:TKNO) Might Not Be As Mispriced As It Looks After Plunging 30%
Jun 27Not Many Are Piling Into Alpha Teknova, Inc. (NASDAQ:TKNO) Stock Yet As It Plummets 25%
Apr 24Health Check: How Prudently Does Alpha Teknova (NASDAQ:TKNO) Use Debt?
Jan 22Some Analysts Just Cut Their Alpha Teknova, Inc. (NASDAQ:TKNO) Estimates
Aug 14Take Care Before Jumping Onto Alpha Teknova, Inc. (NASDAQ:TKNO) Even Though It's 30% Cheaper
Apr 17Alpha Teknova, Inc. (NASDAQ:TKNO) Just Reported, And Analysts Assigned A US$23.00 Price Target
May 14Shareholder Returns
| TKNO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -4.8% | -2.7% | 1.0% |
| 1Y | 216.9% | 11.8% | 33.1% |
Return vs Industry: TKNO exceeded the US Life Sciences industry which returned 11.8% over the past year.
Return vs Market: TKNO exceeded the US Market which returned 33.1% over the past year.
Price Volatility
| TKNO volatility | |
|---|---|
| TKNO Average Weekly Movement | 13.8% |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TKNO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TKNO's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 211 | Stephen Gunstream | www.teknova.com |
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits.
Alpha Teknova, Inc. Fundamentals Summary
| TKNO fundamental statistics | |
|---|---|
| Market cap | US$333.14m |
| Earnings (TTM) | -US$31.68m |
| Revenue (TTM) | US$36.35m |
9.6x
P/S Ratio-11.0x
P/E RatioIs TKNO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TKNO income statement (TTM) | |
|---|---|
| Revenue | US$36.35m |
| Cost of Revenue | US$29.91m |
| Gross Profit | US$6.44m |
| Other Expenses | US$38.12m |
| Earnings | -US$31.68m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.59 |
| Gross Margin | 17.71% |
| Net Profit Margin | -87.17% |
| Debt/Equity Ratio | 15.3% |
How did TKNO perform over the long term?
See historical performance and comparison